APA (7th ed.) Citation

TT, L., JY, W., JS, T., TQ, L., YY, S., & Y, Y. (2026). The sodium-glucose co-transporter 2 inhibitor, empagliflozin, attenuates pulmonary vascular remodelling by inhibiting the phosphorylation of PDGF receptor-β. British journal of pharmacology, 183(9), 1975. https://doi.org/10.1111/bph.70222

Chicago Style (17th ed.) Citation

TT, Lyu, Wang JY, Tan JS, Li TQ, Shu YY, and Yang Y. "The Sodium-glucose Co-transporter 2 Inhibitor, Empagliflozin, Attenuates Pulmonary Vascular Remodelling by Inhibiting the Phosphorylation of PDGF Receptor-β." British Journal of Pharmacology 183, no. 9 (2026): 1975. https://doi.org/10.1111/bph.70222.

MLA (9th ed.) Citation

TT, Lyu, et al. "The Sodium-glucose Co-transporter 2 Inhibitor, Empagliflozin, Attenuates Pulmonary Vascular Remodelling by Inhibiting the Phosphorylation of PDGF Receptor-β." British Journal of Pharmacology, vol. 183, no. 9, 2026, p. 1975, https://doi.org/10.1111/bph.70222.